CA2233300A1 - Paf-acetylhydrolase paf et son utilisation en therapie - Google Patents

Paf-acetylhydrolase paf et son utilisation en therapie Download PDF

Info

Publication number
CA2233300A1
CA2233300A1 CA002233300A CA2233300A CA2233300A1 CA 2233300 A1 CA2233300 A1 CA 2233300A1 CA 002233300 A CA002233300 A CA 002233300A CA 2233300 A CA2233300 A CA 2233300A CA 2233300 A1 CA2233300 A1 CA 2233300A1
Authority
CA
Canada
Prior art keywords
polypeptide
dna
sequence
seq
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002233300A
Other languages
English (en)
Inventor
Christopher Donald Southan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1995/002320 external-priority patent/WO1997012984A1/fr
Priority claimed from GBGB9617781.1A external-priority patent/GB9617781D0/en
Application filed by Individual filed Critical Individual
Publication of CA2233300A1 publication Critical patent/CA2233300A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

On décrit un polypeptide de SEQ ID NO 1, utile en thérapie.
CA002233300A 1995-09-29 1996-09-26 Paf-acetylhydrolase paf et son utilisation en therapie Abandoned CA2233300A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/GB95/02320 1995-09-29
PCT/GB1995/002320 WO1997012984A1 (fr) 1995-09-29 1995-09-29 COMPOSE PRESENTANT UNE HOMOLOGIE DE SEQUENCE AVEC UNE PHOSPHOLIPASE A2 ASSOCIEE A UNE LIPOPROTEINE (Lp-PLA2) OU ACETYLE HYDROLASE DU FACTEUR D'ACTIVATION DES PLAQUETTES
GB9617781.1 1996-08-24
GBGB9617781.1A GB9617781D0 (en) 1996-08-24 1996-08-24 New use

Publications (1)

Publication Number Publication Date
CA2233300A1 true CA2233300A1 (fr) 1997-04-10

Family

ID=26306449

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002233300A Abandoned CA2233300A1 (fr) 1995-09-29 1996-09-26 Paf-acetylhydrolase paf et son utilisation en therapie

Country Status (5)

Country Link
EP (1) EP0859834A2 (fr)
JP (1) JP2002515728A (fr)
AU (1) AU7216996A (fr)
CA (1) CA2233300A1 (fr)
WO (1) WO1997012963A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2267994C (fr) * 1997-08-13 2005-04-12 Icos Corporation Version tronquee de l'acetyl-hydrolase du facteur d'activation plaquettaire
PL209824B1 (pl) 2000-02-16 2011-10-31 Smithkline Beecham Plc 1-(N-2-(dietyloamino)etylo)-N-(4-(4-trifluorometylo-fenylo)benzylo)aminokarbonylometylo)-2-(4-fluorobenzylo)tio-5,6-trimetylenopirymidyn-4-on, jego zastosowania i zawierająca go farmaceutyczna kompozycja
SG190830A1 (en) 2010-12-06 2013-07-31 Glaxo Group Ltd Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2
WO2012080497A2 (fr) 2010-12-17 2012-06-21 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
CA2843102A1 (fr) 2011-07-27 2013-01-31 Glaxo Group Limited Composes pyrimidones bicycliques
AU2012289492B2 (en) 2011-07-27 2016-02-04 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors
AU2014210259B2 (en) 2013-01-25 2016-11-03 Glaxosmithkline Intellectual Property Development Limited Compounds
JP2016505053A (ja) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物
JP6306053B2 (ja) 2013-01-25 2018-04-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２，３−ジヒドロイミダゾール［１，２−ｃ］ピリミジン−５（１Ｈ）−オンに基づくリポタンパク質関連ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）阻害剤
WO2016012916A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
WO2016012917A1 (fr) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2
PE20230092A1 (es) 2019-11-09 2023-01-16 Shanghai Simr Biotechnology Co Ltd Derivado triciclico de dihidroimidazopirimidona, metodo de preparacion del mismo, composicion farmaceuticas y uso del mismo
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69423436T2 (de) * 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
US5641669A (en) * 1993-10-06 1997-06-24 Icos Corporation Platelet-activating factor acetylhydrolase

Also Published As

Publication number Publication date
WO1997012963A2 (fr) 1997-04-10
EP0859834A2 (fr) 1998-08-26
WO1997012963A3 (fr) 1997-06-12
JP2002515728A (ja) 2002-05-28
AU7216996A (en) 1997-04-28

Similar Documents

Publication Publication Date Title
US5817485A (en) Nucleic acids and cells for recombinant production of fibroblast growth factor-10
US20020072107A1 (en) Human osteoclast derived cathepsin
CA2233300A1 (fr) Paf-acetylhydrolase paf et son utilisation en therapie
KR20010020601A (ko) 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
US6300484B1 (en) DNA encoding DP. 75 and a process for its use
US6284504B1 (en) Human DNA ligase III
AU755251B2 (en) Compositions and methods for sensitizing and inhibiting growth of human tumor cells
EP0912747A1 (fr) Protease aspartique
JP2004000215A (ja) 新規トポイソメラーゼｉｉｉ
US9068174B2 (en) Method for sensitizing tumor cells to chemotherapeutic prodrug CPT-11
US5710035A (en) Human elastase IV
JPH10501985A (ja) インターロイキン−１β変換酵素様アポトーシスプロテアーゼ−１および２
FR2723378A1 (fr) Sequence d'adn codant pour une proteine humaine tx apparentee a l'enzyme de conversion de l'interleukine-1beta, proteine tx, procede de production, compositions pharmaceutiques et leurs applications
EP0853673A1 (fr) COMPOSE PRESENTANT UNE HOMOLOGIE DE SEQUENCE AVEC UNE PHOSPHOLIPASE A2 ASSOCIEE A UNE LIPOPROTEINE (Lp-PLA2) OU ACETYLE HYDROLASE DU FACTEUR D'ACTIVATION DES PLAQUETTES
US6518052B1 (en) Human homologue of yeast helicase and uses thereof
CN100390286C (zh) 新酶基因及其表达产物
US6455274B1 (en) Human DNA Ligase IV
CA2233296A1 (fr) Compose presentant une homologie de sequence avec une phospholipase a2 associee a une lipoproteine (lp-pla2) ou acetyle hydrolase du facteur d'activation des plaquettes
US9492510B2 (en) Composition and method for inhibiting tumor cell growth
WO1996012791A1 (fr) Abh humain
EP0796320A1 (fr) Adn-ligase iii humaine

Legal Events

Date Code Title Description
FZDE Dead